IQVIA (NYSE:IQV) Downgraded to Hold Rating by StockNews.com

StockNews.com downgraded shares of IQVIA (NYSE:IQV) from a buy rating to a hold rating in a research note published on Thursday.

IQV has been the subject of a number of other reports. Redburn Atlantic assumed coverage on shares of IQVIA in a research report on Monday, October 14th. They set a “buy” rating and a $276.00 price target for the company. The Goldman Sachs Group reduced their price target on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Robert W. Baird reduced their price target on shares of IQVIA from $256.00 to $223.00 and set a “neutral” rating for the company in a research report on Friday, November 1st. Argus upgraded shares of IQVIA to a “strong-buy” rating in a research report on Wednesday, July 31st. Finally, Barclays cut their target price on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Five equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $256.50.

IQVIA Stock Up 0.1 %

IQV opened at $201.43 on Thursday. The company has a fifty day moving average price of $219.50 and a 200-day moving average price of $226.40. The firm has a market capitalization of $36.56 billion, a P/E ratio of 26.43, a price-to-earnings-growth ratio of 2.10 and a beta of 1.51. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. IQVIA has a one year low of $187.62 and a one year high of $261.73.

Hedge Funds Weigh In On IQVIA

Hedge funds and other institutional investors have recently modified their holdings of the company. Capital Performance Advisors LLP bought a new position in shares of IQVIA during the third quarter valued at about $27,000. Park Place Capital Corp bought a new position in shares of IQVIA during the third quarter valued at about $28,000. Versant Capital Management Inc raised its stake in shares of IQVIA by 733.3% during the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 110 shares during the last quarter. Opal Wealth Advisors LLC bought a new position in shares of IQVIA during the second quarter valued at about $27,000. Finally, Itau Unibanco Holding S.A. bought a new position in shares of IQVIA during the second quarter valued at about $29,000. 89.62% of the stock is owned by institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.